Do GLP-1 weight loss plateaus mean your medication stopped working?

What did @betterlivingforeveryone actually say?

The creator, who identifies as a physician assistant, laid out four reasons a scale might stall during GLP-1 therapy: water retention from inflammation, stress, hormones, or sodium; metabolic adaptation as body weight drops; under-eating and under-consuming protein; and constipation. They said a plateau lasting under four to six weeks is normal, and only after that point should patients contact their provider about a possible dose adjustment.

They also pushed tracking body measurements alongside scale weight, arguing that fat loss can continue even when the number on the scale sits still. The video ends with a soft call to follow for more tips, which is standard creator behavior but worth noting given that advice comes attached to a sales funnel.

Does the science back this up?

Mostly, yes. The core claims here are not invented. There is solid mechanistic and clinical evidence for most of what they described, though some of it is oversimplified in ways that matter.

Metabolic adaptation is real and well-documented. Leibel et al. (1995, New England Journal of Medicine) showed that weight loss produces a reduction in total energy expenditure beyond what body composition changes alone would predict. That effect has been replicated in GLP-1 trial data: participants in STEP 1 (Wilding et al., 2021, NEJM) who lost significant weight on semaglutide still showed the expected downward shift in resting metabolic rate as mass dropped.

The protein argument also has backing. Kohanmoo et al. (2020, Nutrition, Metabolism and Cardiovascular Diseases) found that higher protein intake during caloric restriction preserves lean mass, which is directly relevant because GLP-1 medications suppress appetite broadly and can lead to inadequate protein intake. The constipation point, while unglamorous, is accurate. Gastrointestinal slowing is a pharmacologic effect of GLP-1 agonists. Fecal mass contributing to scale weight is real, if modest.

What did they get wrong (or right)?

They got the broad framework right. But two things deserve pushback.

First, the claim that a plateau "doesn't necessarily mean that fat loss is stopping" is presented with more confidence than the evidence supports. Water retention can mask fat loss for days, maybe one to two weeks. A full month of scale stagnation with no measurable change in circumference measurements is a different clinical picture, and the video blurs that distinction. The creator should have been clearer that a four-week plateau warrants earlier attention, not reassurance until the deadline arrives.

Second, "not eating enough" causing metabolism to "ratchet back another notch" is directionally correct but mechanistically vague. The adaptive thermogenesis literature is nuanced. Rosenbaum and Leibel (2010, International Journal of Obesity) found that the metabolic penalty of severe under-eating is real but variable across individuals and not fully reversible just by eating more. Telling patients to "make sure you're eating plenty" without flagging that GLP-1 medications can suppress hunger signals to the point where patients genuinely cannot tell they are under-eating is an important omission for a clinician-creator.

• The four-to-six-week rule for contacting a provider is reasonable and consistent with general clinical practice guidance.
• The recommendation to take measurements before starting medication is genuinely good advice that many patients skip.
• The constipation explanation is accurate and underappreciated.

What should you actually know?

If you are on a GLP-1 medication and the scale has stopped moving, this video is not wrong to tell you not to panic immediately. But here is what the video does not tell you clearly enough.

GLP-1 medications reduce appetite substantially. In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), tirzepatide participants at higher doses reported significant reductions in hunger scores. That suppression can make it genuinely difficult to reach adequate caloric and protein thresholds, and patients may not feel under-eaten. Tracking food intake, not just trusting hunger cues, matters on these medications.

Plateaus that persist beyond four weeks are not always a sign to increase your dose. They can reflect inadequate protein, disrupted sleep, elevated cortisol, or a medication adherence issue. A dose adjustment is one tool, not the default answer. And if you are on a compounded version of semaglutide or tirzepatide, your dosing consistency may differ from the clinical trial populations where these plateau patterns were studied. Talk to your prescribing provider before adjusting anything.

The video is educational content from someone who appears credentialed, but it is not a substitute for a conversation with your own clinician who knows your full history.